Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project by Kramar, A et al.
1 
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
Guidelines for the definition of time to event endpoints in renal cell cancer 
clinical trials: results of the DATECAN project 
 
A. Kramar1, S. Negrier2, R. Sylvester3, S. Joniau4, P. Mulders5, T. Powles6, A. 
Bex7, F. Bonnetain8, A. Bossi9, S. Bracarda10, R. Bukowski11, J. Catto12, T.K. 
Choueiri13, S. Crabb14, T. Eisen15, M. El Demery16, J. Fitzpatrick17, V. Flamand18, 
P.J. Goebell19, G. Gravis20, N. Houédé21, D. Jacqmin22, R. Kaplan23, B. 
Malavaud24, C. Massard9, B. Melichar25, L. Mourey26, P. Nathan27, D. Pasquier28, 
C. Porta29, D. Pouessel30, D. Quinn31, A. Ravaud32, F. Rolland33, M. 
Schmidinger34, B. Tombal35, D. Tosi36, E. Vauleon37, A. Volpe38, P. Wolter39, B. 
Escudier9, T. Filleron26, on behalf of the DATECAN Renal Cancer group 
 
1Methodology and Biostatistics Unit, Centre Oscar Lambret and SIRIC ONCO LILLE, 
Lille, France 
2Medical Oncology Department, University of Lyon I, Centre Léon Bérard, Lyon, 
France 
3Department of Biostatistics, EORTC Headquarters, Brussels, Belgium 
4Department of Urology, University Hospitals Leuven, Leuven, Belgium 
5Department of Urology, Radboud University Medical Centre, Nijmegan, the 
Netherlands 
6Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary 
University of London, London, United Kingdom 
7Department of Urology, The Netherlands Cancer Institute-Antoni Van 
Leeuwenhoekziekenhuis, Amsterdam, The Netherlands 
 Annals of Oncology Advance Access published September 14, 2015
 at N
etherlands Cancer Institute on Septem
ber 16, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
2 
8Methodology and Quality of Life in Oncology Unit , University Hospital of Besançon, 
Besançon, France 
9Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France 
10Department of Oncology, Ospedale San Donato, Arezzo, Italy 
11Department of Immunology, Cleveland Clinic Taussig Cancer Center, Cleveland, 
USA 
12Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom 
13Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber 
Cancer Institute, Boston, USA 
14Cancer Sciences Unit, University of Southampton Faculty of Medicine, 
Southampton, United Kingdom 
15Department of Oncology, Cambridge University Health Partners, Cambridge, 
United Kingdom 
16Department of Medical Oncology, University Hospital of Nîmes, Nimes, France 
17Division of Surgery, Mater Misericordiae Hospital and University College Dublin, 
Dublin, Ireland 
18Department of Urology, University Lille2 Nord de France, Lille, France 
19Department of Urology, Friedrich-Alexander University Erlangen-Nueremberg, 
Erlangen, Germany  
20Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France 
21Department of Medical Oncology, CHU Caremeau, Nîmes, France 
22Department of Urology, CHRU, Strasbourg, France 
23MRC Clinical Trials Unit, University College London, London, UK 
24Department of Urology, CHU, Toulouse, France 
 at N
etherlands Cancer Institute on Septem
ber 16, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
3 
25Department of Oncology, Palacký University Medical School and Teaching 
Hospital, Olomouc, Czech Republic 
26Medical Oncology Department,Institut Claudius Regaud, Institut Universitaire du 
Cancer-Oncopole, Toulouse France 
27Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, 
Middlesex, United Kingdom 
28Academic Radiation Oncology Department, Centre Oscar Lambret and SIRIC 
ONCO LILLE, Lille, France 
29Department of Medical Oncology, Fondazione IRCCS Policlinico San Matteo, 
Pavia, Italy 
30Medical Oncology Department, Hôpital Saint-Louis, APHP, Paris, France  
31Division of Oncology, USC Norris Comprehensive Cancer Center and Hospital, Los 
Angeles, USA 
32Department of Medical Oncology, Hôpital Saint André, Bordeaux, France 
33Department of Medical Oncology, Institut de cancérologie de l'Ouest - René 
Gauducheau, Nantes, France 
34Department of Medicine I, Clinical Division of Oncology and Comprehensive 
Cancer Center,Medical University of Vienna, Vienna, Austria 
35Department of Urology, Cliniques universitaires Saint Luc, Brussels, Belgium 
36Department of Medical Oncology, Institut Régional du Cancer Val d’Aurelle, 
Montpellier, France 
37Department of Medical Oncology, Centre Eugène Marquis, Rennes, France 
38Division of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, 
Novara, Italy 
 at N
etherlands Cancer Institute on Septem
ber 16, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
4 
39Department of General Medical Oncology, University Hospitals Leuven, Leuven 
Cancer Institute, Leuven, Belgium 
 
Supported by a grant from Ligue Nationale Contre le Cancer 
 
Corresponding author: Dr Thomas FILLERON, Bureau des Essais Cliniques – Cellule 
Biostatistique, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse - 
Oncopole, 1 avenue Irène Joliot-Curie, 31059 TOULOUSE Cedex 9, 
filleron.thomas@iuct-oncopole.fr, Tél : +33 (0) 531 155 865 
 
This work was presented as a poster communication at ESMO (Madrid. Sept 2014). 
 
Key Message: "In this report, results from a panel of expert clinicians in renal cell cancer have come up with a 
consensus for defining selected time to event endpoints in renal cell cancer. It should now be easier to 
compare results from studies when evaluating therapies in both the adjuvant and advanced disease setting." 
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ABSTRACT 
 
Background 
In clinical trials, the use of intermediate time to event endpoints (TEE) is increasingly 
common, yet their choice and definitions are not standardized. This limits the usefulness for 
comparing treatment effects between studies. The aim of the DATECAN Kidney project is to 
clarify and recommend definitions of TEE in renal cell cancer (RCC) through a formal 
consensus method for endpoint definitions.  
Material and Methods 
A formal modified Delphi method was used for establishing consensus. From a 2006-2009 
literature review, the Steering Committee (SC) selected 9 TEE and 15 events in the non-
metastatic (NM) and metastatic/advanced (MA) RCC disease settings. Events were scored 
on the range of 1 (totally disagree to include) to 9 (totally agree to include) in the definition of 
each endpoint. Rating Committee (RC) experts were contacted for the scoring rounds. From 
these results, final recommendations were established for selecting pertinent endpoints and 
the associated events.  
Results 
Thirty-four experts scored 121 events for 9 endpoints. Consensus was reached for 31%, 
43% and 85% events during the first, second and third rounds respectively. In the NM 
setting: Disease-Free Survival (contralateral renal cell cancer, appearance of metastases, 
local or regional recurrence, death from RCC or protocol treatment), Metastasis-Free 
Survival (appearance of metastases, regional recurrence, death from RCC); and Local 
Regional Free-Survival (local or regional recurrence, death from RCC). In the MA setting: 
Kidney Cancer Specific Survival (death from RCC or protocol treatment) and Progression-
Free Survival (death from RCC, Local, regional, or metastatic progression). 
Conclusions 
The consensus method revealed that intermediate endpoints have not been well defined, 
since all of the selected endpoints had at least one event definition for which no consensus 
was obtained. These clarified definitions of TEE should become standard practice in all RCC 
clinical trials, thus facilitating reporting and increasing precision in between trial comparisons.  
 
Keywords: Clinical trials, DATECAN, Recommendations, Renal cell cancer, Time to event 
endpoints. 
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Introduction 
Many different time-to-event endpoints are used in evaluating treatment in cancer 
clinical trials in general, and for trials of patients with renal cell cancers (RCC) 
specifically. Except for overall survival (OS), their definitions are not standardized and 
can be composed of different event types. Thus, endpoints such as Relapse-Free 
Survival (RFS) or Disease-Free Survival (DFS) can be considered composite 
endpoints since several different event types are included in their definition.  
Even though these types of endpoints are being widely used, they are usually poorly 
defined and are commonly specific to each particular trial being analyzed as 
underlined by Mathoulin et al (1) and by the Food and Drug Administration (FDA) (2). 
For example, several adjuvant trials have used different events for DFS (3). In the S-
TRAC clinical trial, comparing sunitinib and placebo for the treatment of patients at 
high risk of recurrent renal cell cancer, considered the following events for disease-
free survival : recurrence,  secondary malignancy or death (4). In the ASSURE phase 
III randomize trial comparing sunitinib to sorafenib to placebo in patients with kidney 
cancer removed by surgery, considered the following events for disease-free survival: 
recurrence, second primary cancer, or death from any cause (5). In the SORCE 
phase III double blind randomized trial comparing sorafenib to placebo in patients 
with resected primary RCC in high or intermediate risk of relapse considered the 
following events for disease-free survival  : local recurrence, distant metastases or 
death from RCC (6). The same variations are observed in trials conducted in 
metastatic patients including pivotal trials that led to the registration of investigational 
compounds. For instance, PFS analysed in the sorafenib registration trial, takes into 
account the date of progression only (7) . On the contrary, PFS analysed in the 
sunitinib registration trial was calculated with the dates of progression or death from 
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any cause (8) .The lack of clear standardized definitions for the same named 
endpoints can limit the interpretation of results when using different event types in the 
definition of endpoints in clinical trials (2, 9).  
Moreover, the primary endpoint directly impacts trial results by affecting estimation of 
treatment effects and statistical power as shown by Nout for breast cancer (10). Also, 
in order to allow cross-comparisons of results between trials, or just to use this 
information in the planning of future trails, the events as well as the censoring rules 
need to be clearly defined for each of the events that are combined in the composite 
time-to-event endpoints (1).. 
Recent publications have attempted to address this issue by proposing endpoint 
definitions in adjuvant colorectal cancer (11), in hepatocellular cancer (12) and in 
breast cancer (13). However, these studies did not use an explicit consensus 
method. Moreover the experts involved were not necessarily representative of the 
many academic groups involved in cancer trials. Moreover to the best of our 
knowledge, no definition of endpoints has so far been proposed in kidney cancer.  
This study has 2 main objectives: first, to better defining endpoints that are frequently 
used in adjuvant or metastatic setting for RCC patients, second, to identify the most 
appropriate endpoints and make recommendations for use in future trials. In this 
idea, RAND methodology, based on a large panel of experts involved in kidney 
cancer clinical trials, was used to provide consensus definitions on primary and 
secondary endpoints. This project is part of the DATECAN project (Definition for the 
Assessment of Time-to-event Endpoints in CANcer trials) whose final aim is to obtain 
harmonized consensus definitions for various cancer sites (14).  
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Methods 
The project was developed by the DATECAN Study Group. The methodology was 
first developed and applied in 3 tumor types, including pancreatic cancer (15), 
sarcoma-GIST (16) and breast cancer (17). The present methodology has already 
been extensively described elsewhere (14).  
 
Literature Review 
Based on a PubMed literature search (Supplementary Data S1), the first step 
involved a search to see if guidelines had not already been developed for the 
definitions of time-to-event endpoints in kidney CRT. After a first selection from the 
abstracts of the 952 articles identified, no formal consensus on the definition of time-
to-event endpoints was identified. Therefore, renal cell cancer was judged to be an 
eligible cancer type for this project. 
 
Consensus process 
Formalized consensus using modified Delphi with Rand scoring methodology was 
used to reach consensus (18-20). This method involves six steps: assessment of 
evidence; elaboration and pre-testing of the questionnaire; scoring of the 
questionnaires; analysis of the experts’ opinions and drafting of the final report; peer-
review; diffusion of the recommendations (Figure 1).  
 
Questionnaires 
For the first round, all Rating Committee experts (RC) received the questionnaire 
elaborated by the Steering Committee (SC) (Supplementary table 1). The RC were 
asked to indicate on a scale ranging from 1 (totally disagree) to 9 (totally agree) 
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whether each event should be regarded or not as an event in the definition of each 
endpoint. At the second round, the experts scored only those items for which 
consensus had not been reached after the first round (Supplementary table 2). 
Based on the first round distribution of scores and their own initial score, each expert 
was asked to either maintain or modify their initial score. Items for which no strong 
consensus had been reached were discussed during an in-person meeting involving 
members of the SC and RC. A representative of the DATECAN Study Group led this 
meeting, where a preliminary draft of the recommendations was written and sent for 
validation to all experts.  
The SC underlined the fact that defining censoring rules are statistical issues rather a 
clinical question. Indeed, it is common practice to classify events which are not 
included in the definition at the stage of the statistical analysis plan. This can lead to 
ignoring, censoring or treating them as competing events. As a result, censoring of 
other events was not discussed during the consensus process. 
Following a preliminary review by the SC and RC, the first draft of the 
recommendations was presented to the DATECAN Study Group for approval.  
 
 
Results 
Literature search 
When this project was initiated in 2010, a systematic review identified 151 
publications of clinical trials in kidney cancer published between 2005 and 2009. Two 
disease settings were identified: metastatic/advanced and non metastatic. Nine time-
to-event endpoints retained by the SC included Kidney Cancer Specific Survival 
(KCSS), Disease – Free Survival (DFS), Relapse–Free Survival (RFS), Metastasis–
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10 
Free Survival (MFS), Local Recurrence–Free Survival (LRFS), Local Regional–Free 
Survival (LGFS), Failure–Free Survival (FFS), Progression–Free Survival (PFS) and 
Time To Progression (TTP). 
The following events were identified: Contra lateral kidney cancer, Appearance of 
metastases, Local recurrence, Regional recurrence, Second primary invasive cancer 
(non-kidney), Local progression, Regional progression, Progression of metastases, 
Death from kidney cancer, Death related to a second cancer, Death from non-kidney 
cancer cause, Death related to protocol treatment, Death from any cause and Death 
from unknown cause. Even though not formally identified in the literature search, the 
SC decided to include the following events related to reasons for end of treatment: 
toxicity related to treatment, adverse event unrelated to treatment, and patient refusal 
or investigator choice. Finally, loss to follow-up was also included as an event for all 
endpoints. Thus a total of 18 distinct event types were used, not all of which were 
pertinent to both disease settings. 
Consensus rounds 
Two rating rounds (first round: 07/2012 to 09/2012; second round 10/2012 to 
01/2013), the in-person meeting (05/2013), and the steering committee meeting 
(03/2014) took place and led to the development of the recommendations described 
below. 
First and second rounds 
Fifty-two experts were contacted, with 36 (63.5%) and 34 (94%) participants in each 
round respectively. Specialities included medical oncologists (21), radiation 
oncologists (2), urologists (9), hematologic oncologists (1), and biostatistician (1). 
Academic groups from nine European countries were involved. Even though few 
biostatisticians were involved in the review process, the pilot group was composed of 
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three statisticians who helped in the interpretation of results. The experts were 
chosen for their involvement in kidney cancer trials and patient care and for their 
implication in interpreting results from clinical trials when choosing appropriate 
treatment for their patients.  
Overall, experts scored 156 events pertaining to the 9 endpoints, two of which were 
common to both the metastatic and non-metastatic settings (KCSS and FFS). After 
the first round, four events relating to reasons for treatment end and loss to follow-up 
were no longer considered (100% consensus). Among the remaining 121 events, 
31% consensus was reached, 36% (15/42) and 29% (23/79) in the metastatic and 
non-metastatic disease settings respectively (tables 1A,1B). After the second round, 
43% consensus was reached, 40% (17/42) and 44% (35/79) respectively (tables 
1A,1B). 
In-person meeting (Budapest, 05/2013) 
During the face-to-face meeting, rules for consensus allowed greater tolerance for 
missing or extreme scores (Supplementary table 2). Interesting comments raised 
several questions, notably the precise definition of events. Also, some endpoints 
were not considered relevant and practical in evaluating certain treatment strategies.  
Other comments related to terminology such as “survival” in those endpoints where 
this term was included, such as DFS. This may have confused some experts since 
events are more related to failure than survival. It also became clear that certain 
causes of death were difficult to classify due to ambiguity in certain items. For 
example, if death from any cause was excluded as an event, death related to 
protocol treatment and from unknown cause should also have been excluded. This 
ambiguity could have led to different interpretations of the events themselves by 
members of the RC.  
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After the face-to-face meeting, 82% consensus was reached for 103 events, 81% 
(34/42) and 87% (69/79) respectively (tables 1A,1B). No consensus was reached for 
18 events and concerned all endpoints. 
Contralateral kidney cancer was the most controversial event that concerned four 
endpoints. For example there were 13 votes to exclude and 15 votes to include this 
event for KCSS after the second round in both disease settings.  
There were 16 votes to exclude and 13 votes to include death related to a second 
cancer for FFS in both settings. No consensus was reached for the following: death 
related to protocol treatment for PFS in the metastatic setting and RFS and LGFS in 
the non-metastatic setting; death from any cause for FFS and PFS in the metastatic 
setting and DFS, RFS and FFS in the non-metastatic setting; and death from 
unknown cause for PFS in the metastatic setting and MFS and LGFS in the non-
metastatic setting (Tables 1A,1B).  
The face-to-face meeting results were summarized by the SC in a preliminary report 
that was circulated for comment and approval by the RC who attended the meeting. 
Even after the three rounds of scoring, the consensus method revealed that 
intermediate TEE endpoints have not previously been well defined, since all of the 
selected endpoints had at least one event definition for which no consensus was 
obtained. The SC compiled the results in the document which was updated in 
10/2013 and electronically submitted to the RC who validated the final version of the 
recommendations. The final version was approved in 03/2014 during the SC meeting.  
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Recommendations  
After the face-to-face meeting, the results were compiled by the SC from the three 
rounds in order to come up with recommendations. The SC recommended the use of 
only two endpoints in the metastatic/advanced disease (Kidney Cancer Specific 
Survival (KCSS), Progression-Free-Survival (PFS)) and only three endpoints 
(Disease-Free-Survival (DFS), Metastasis-Free-Survival (MFS), Local-Regional-
Free-Survival (LGFS)) in non-metastatic disease setting. The final version of the 
recommendations was then approved by the RC. All time-to-event endpoints were 
defined as the time interval between the date of reference (date of inclusion, date of 
randomization, date of diagnosis, etc …) to the endpoint in question. The following 
definitions were consensually agreed upon: 
 
Metastatic/Advanced Setting events: 
 KCSS: death from kidney cancer or death from protocol treatment, whichever 
occurs first. 
 PFS: death from kidney cancer or local, regional or metastatic progression, 
whichever occurs first. 
 
Non-Metastatic Setting events: 
 DFS: death from protocol treatment or from kidney cancer or local, regional 
recurrence, or metastases or contra lateral kidney cancer, whichever occurs 
first. 
 MFS: death from kidney cancer, or appearance of metastases, whichever 
occurs first. 
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14 
 LGFS: death from kidney cancer or Local or regional recurrence, whichever 
occurs first. 
 
 
Discussion 
The aim of this project was to recommend and define time-to-event endpoints in 
kidney cancer clinical trials in both the adjuvant and metastatic disease settings using 
a formal consensus methodology which brought together opinions from many experts 
from different fields in oncology in a three round exercise as opposed to investigator-
based non universal definitions for a specific treatment protocol.  
A majority of trials in kidney cancer assess one or two time-to-event endpoints. The 
most common primary endpoints were DFS and PFS in the adjuvant and metastatic 
settings respectively. The secondary endpoints were generally MFS and OS in the 
adjuvant setting and OS or KCSS in the metastatic setting.  
Until recently, precise definitions of these endpoints were not an issue in the adjuvant 
setting due to the failure of most treatments (Pal & Haas ex-ref 15). However, since 
results can be expected in the near future, this issue is now important. Very few face-
to-face comparative trials betwen the 7 different targeted therapies registered for 
mRCC patients are available. Therefore, prescribers often balance the results of the 
PFS obtained with each compound throughout the different trials despite the fact that 
this endpoint does not consider the same events in every trial. One could wonder if 
the use of a different definition for a particular endpoint may affect the conclusion of 
these studies. It has already been shown in the context of colorectal cancer (21) and 
of breast cancer (10) that varying the definitions for a particular time-to-event 
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endpoint can strongly impact the estimation of time-to-event rates as well as the 
trial’s conclusions by affecting both statistical power and estimation.  
This situation reinforces the need for clear endpoints because inter-trial comparisons 
or cross-trial evaluations will be done and meta-analysis could be undertaken at 
some point. Therefore, the adjuvant setting represents a big challenge in a highly 
competitive context. We thus propose to take into account our recommendations for 
the future analysis of these trials.  
In the metastatic setting, the majority of randomized studies did not show an OS 
advantage, mainly due to the use of active treatments after failure of the initial 
therapy. It is thus important to use exact definitions for endpoints which will be 
measuring the range of benefit that can be expected both in future trials and routine 
practice.  
The lack of consensus regarding the definition of time-to-event endpoints other than 
OS was confirmed by the first round results with only 31% consensus, thus 
underlining the variability in the endpoint definitions among experts involved in kidney 
cancer trials. For the endpoint “Kidney cancer-specific survival”, consensus regarding 
whether to include death related to protocol treatment in the endpoint was not 
reached even after the second round. This may be due to a lack of clarity in the 
interpretation of the event “death due to protocol treatment”. The definition may 
reflect different opinions amongst experts regarding the likely impact of a treatment. 
The choice of a particular endpoint was not addressed in this paper since some 
endpoints occur earlier than others and some may be more appropriate to certain 
situations. For instance, it may be more appropriate to consider cancer specific 
endpoints in elderly patients due to co-morbidities and the increased risk of death 
due to other causes in this population. This opinion may relate to the specialty of the 
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expert: urologic surgeon, medical oncologist or radiotherapist, since each specialist 
may have a different view on the outcome of patients and consider some events 
irrelevant. The time-to-event endpoints were selected after a literature review of 
published clinical trials. Although all of the 9 endpoints that were finally kept and 
better defined, are frequently used, they can be relevant in specific trials dependent 
on the treatments under investigation. As a result, the SC identified the use of two 
most appropriate endpoints in the metastatic disease setting (Kidney-Cancer-
Specific-Survival, Progression-Free-Survival) and three endpoints in the non-
metastatic setting (Disease-Free-Survival, Metastasis-Free-Survival, Local-Regional-
Free-Survival).  
International recommendations obtained through a formal and validated consensus 
process, as well as the active participation of experts from various institutions and 
specialties in this project, should increase the acceptability of the resulting 
recommendations and contribute to their wide scale implementation in future 
research.  
Using clearly defined and easy to use “conservative” definitions will enable an easier 
endorsement and general use in the evaluation of treatment strategies and should 
thus contribute to avoiding misinterpretations of results, which apply to both primary 
and secondary endpoints. We suggest that the definitions of the endpoints, as 
chosen by the expert panel, should be adopted for use in future RCC clinical trials. 
This will ensure the interpretation of the results and facilitate the unformal inter-trial 
comparisons. Future perspectives include evaluations of the impact of the use of 
these definitions on results from existing or future trials in kidney cancer. 
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Figure legends 
 
Figure 1: Modified Delphi method used to reach consensus for survival/ time to event 
endpoints in kidney cancer trials. 
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Table 1A. Metastatic/advanced disease setting: results of first and second rounds, face-
to-face meeting 
 
 
ENDPOINT 
EVENT 1. KCSS 7. FFS 8. PFS 9. TTP 
Contra lateral kidney cancer NO IN-2 NO NO 
Appearance of metastases TO IN-1 n/a n/a 
Local recurrence TO IN-1 n/a n/a 
Regional recurrence TO IN-1 n/a n/a 
2nd primary invasive cancer (non-kidney) O-1 TO n/a n/a 
Local progression n/a n/a IN-1 IN-1 
Regional progression n/a n/a IN-1 IN-1 
Progression of metastases n/a n/a IN-1 IN-1 
     Death from kidney cancer IN-1 IN-1 IN-1 TI 
Death related to a second cancer O-1 NO TO TO 
Death from non-kidney cancer cause O-1 TO TO TO 
Death related to protocol treatment TI IN-2 NO TO 
Death from any cause TO NO NO TO 
Death from unknown cause TO TI NO TO 
 
Legend: NO: No consensus; IN-1; Include event first round; O-1; Exclude event first round; IN-2; 
Include event second round; O-2; Exclude event second round; TI; tendency to include during 
face-to-face meeting: TO: tendency to exclude during face-to face meeting; n/a: not applicable 
Endpoints: 1. Kidney Cancer Specific Survival; 7. Failure Free Survival; 8. Progression Free 
Survival; 9.Time To Progression  
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Table 1B. Non metastatic setting: results of first and second rounds, face-to-face meeting 
 
 
ENDPOINT 
EVENT 1.KCSS 2.DFS 3.RFS 4.MFS 5.LRFS 6.LGFS 7.FFS 
Contra lateral kidney cancer NO IN-2 IN-2 NO O-2 TO IN-2 
Appearance of metastases TO IN-1 IN-1 IN-1 O-2 O-2 n/a 
Local recurrence TO IN-1 IN-1 TO IN-1 IN-1 n/a 
Regional recurrence TO IN-1 IN-1 TI TI IN-1 n/a 
Second primary invasive 
cancer (non-kidney) O-1 TO O-1 O-1 O-1 O-1 n/a 
Local progression TO n/a n/a n/a n/a n/a IN-1 
Regional progression TO n/a n/a n/a n/a n/a IN-1 
Progression of metastases TO n/a n/a n/a n/a n/a IN-1 
        Death from kidney cancer IN-1 IN-1 IN-2 IN-2 IN-2 IN-2 IN-1 
Death related to a second 
cancer O-1 TI TO TO TO TO NO 
Death from non-kidney 
cancer cause O-1 TO TO TO TO TO TO 
Death related to protocol 
treatment TI IN-2 NO TO TO NO IN-2 
Death from any cause TO NO NO TO TO TO NO 
Death from unknown cause TO TO TI NO NO TO TI 
 
Legend: NO: No consensus; IN-1; Include event first round; O-1; Exclude event first round; IN-2; 
Include event second round; O-2; Exclude event second round; TI; tendency to include during 
face-to-face meeting: TO: tendency to exclude during face-to face meeting; n/a: not applicable 
Endpoints: 1. Kidney Cancer Specific Survival; 2. Disease Free Survival; 3. Relapse Free 
Survival; 4. Metastasis-Free Survival; 5. Local Recurrence-Free Survival; 6. Loco ReGional 
Free Survival; 7. Failure Free Survival 
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